U.S. restrictions on Chinese biotech could harm patients, argues editorial
By
The Economist
Summary
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tech war that could harm patients. It highlights proposed legislation to amend the COINS Act to include Chinese biotech licensing, and calls to disregard Chinese clinical-trial data by the FDA. The core argument is that patients benefit from faster, cheaper treatments regardless of where they are invented.
Source
Twitter / XU.S. restrictions on Chinese biotech could harm patients, argues editorialeconomist.comKey quotes
· 3 pulledSomeone whose life is saved by a new medicine is unlikely to care whether it was invented at home or on the other side of the world.
America's policymakers have begun treating China's biotechnology industry as the next front in the tech war.
Patients benefit from faster, cheaper treatments, wherever they are invented
You might also wanna read
U.S. restrictions on Chinese biotechnology could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
econ.st·2d ago
U.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict Chinese biotechnology, framing it as an extension of the tech war that would harm patien
econ.st·2d ago
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
China has established a new regulatory "tech track" for advanced therapies like personalized cancer treatments, cell and gene therapies, and
biopharmadive.com·7d ago
China's healthcare sector faces higher barriers than EVs in global innovation push
China's healthcare sector is emerging as a potential new frontier for innovation and globalization, following the success of its electric ve
weforum.org·5h ago
AI leaders unite in call for US regulations to prevent AI-aided bioweapon development
AI industry rivals including Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman have united in an open letter t
buff.ly·18d ago
Manufacturing and regulatory hurdles threaten cell and gene therapy progress
The article discusses how manufacturing and regulatory challenges are hindering the progress of cell and gene therapies, particularly in can
medium.com·8d agoComments
Sign in to join the conversation.
No comments yet. Be the first.